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ABSTRACT
The in-vitro activity of nikkomycin Z was investigated in combination with polyenes, triazoles or
echinocandins against 20 clinical isolates of Aspergillus fumigatus with the fractional inhibitory
concentration index (FICI) method. The drug interactions were classified as synergic (FICI £ 0.5), no
interaction (FICI > 0.5, but FICI £ 4) or antagonistic (FICI > 4). The fungicidal activity of nikkomycin
Z alone and in combination with a representative echinocandin (caspofungin) or triazole (voricon-
azole) was also examined with time-kill experiments and fungal cell viability assays. Two-drug
combinations of nikkomycin Z with amphotericin B (FICI 3.59 ± 0.57), amphotericin B lipid complex
(FICI 3.95 ± 0.74), liposomal amphotericin B (FICI 3.62 ± 0.98), itraconazole (FICI 2.0 ± 0.0), voricon-
azole (FICI 1.07 ± 0.37), posaconazole (FICI 2.20 ± 0.44) or ravuconazole (FICI 1.76 ± 0.44) showed no
interactions, but the pairwise combination of nikkomycin Z with caspofungin (FICI 0.22 ± 0.19) or
micafungin (FICI 0.35 ± 0.27) showed synergic activity against A. fumigatus. Time-kill studies and
fungal cell viability assays showed that neither nikkomycin Z nor caspofungin alone possessed
fungicidal activity against A. fumigatus, whereas a combination of these two drugs at concentrations
‡ 2 mg ⁄L (‡ 0.031 · the concentration of drug that produced no visible growth) killed germinated
conidia within 24 h in a concentration-dependent manner. These data suggest that two-drug
combinations of nikkomycin Z with echinocandins, but not with polyenes and triazoles, have a
synergic effect against A. fumigatus.
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INTRODUCTION
The incidence of invasive aspergillosis has
increased in the past decade as a result of more
widespread use of aggressive chemotherapy reg-
imens against cancer, an increasing population of
patients suffering from AIDS, and the expansion
of organ transplantation programmes. Although
the incidence of fungal infection has increased
significantly over the past decade, only modest
progress has been made in the treatment and
management of Aspergillus infection. Ampho-
tericin B, itraconazole and voriconazole are the
therapeutic options for invasive aspergillosis, but
give less than optimal results. Since amphotericin
B interferes with renal function, less nephrotoxic,
but considerably more expensive, lipid formula-
tions of amphotericin B have been introduced,
with modest success [1–4].
The nikkomycins, echinocandins, triazoles and
polyenes are different classes of antifungal
drugs with distinct modes of action. Chitin is a
polysaccharide found in most fungal cell walls,
including Aspergillus spp. The nikkomycins inhi-
bit chitin synthesis by acting as competitive
analogues of the chitin synthase substrate UDP–
N-acetylglucosamine [5–7]. Similarly, the echino-
candins are cyclic lipopeptide compounds that
inhibit glucan synthesis by inhibiting the
enzyme 1,3-b-D-glucan synthase [8–12]. Lack of
chitin and glucan in the cell wall often leads to
osmotic lysis of the fungal cell. The triazoles and
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the polyenes interfere with the fungal plasma
membrane function by either inhibiting the
synthesis of ergosterol (triazoles) or binding to
it (polyenes), thereby making the membrane a
non-selective cellular barrier.
Since the current single-drug therapeutic
approach against invasive aspergillosis gives sub-
optimal results, the use of antifungal drugs in
combination may be an alternative strategy.
Combination treatment may have several advan-
tages, namely enhanced efficacy, reduced toxicity
by virtue of using lower doses of agents with
adverse side effects, decreased incidence of
in-vivo selection of drug-resistant variants, and
a broader spectrum of activity. Although nikko-
mycin Z has an inhibitory effect on fungal growth,
this compound by itself is not a potent antifungal
drug against Aspergillus spp. [13,14]. However,
because of its low toxicity and high antifungal
specificity, it is suitable for use in combination
with other antifungal drugs. The present study
investigated the in-vitro activity of two-drug
combinations of nikkomycin Z with echinocan-
dins, triazoles, and conventional and lipid for-
mulations of amphotericin B, against Aspergillus
fumigatus.
MATERIALS AND METHODS
Antifungal drugs
Voriconazole, itraconazole, posaconazole and ravuconazole
were obtained from Pfizer Pharmaceuticals (New York, NY,
USA), Janssen Pharmaceutica (Beerse, Belgium), Schering-
Plough Research Institute (Kenilsworth, NJ, USA) and Bristol-
Myers Squibb Institute for Medical Research (Princeton, NJ,
USA), respectively. Amphotericin B was purchased from
Sigma Chemical Company (St Louis, MO, USA). Amphotericin
B lipid complex was obtained from Elan Pharmaceuticals (San
Diego, CA, USA). Caspofungin was obtained from Merck
(Rahway, NJ, USA), and micafungin and liposomal ampho-
tericin B were obtained from Fujisawa Pharmaceuticals
(Osaka, Japan). The triazoles and amphotericin B were dis-
solved in dimethylsulphoxide to make a stock solution of
1 g ⁄L, and then stored as 0.25-mL aliquots at ) 20C. Caspo-
fungin, micafungin and nikkomycin Z were dissolved in sterile
double-distilled water to a concentration of 10 g ⁄L, and were
stored as 0.25-mL aliquots at ) 70C. Frozen stocks of the
antifungal agents were thawed at room temperature and used
within 24 h.
Clinical isolates
The 20 clinical isolates of A. fumigatus used in this study
were selected randomly from our collection of cultures
(n = 619), obtained from the Microbiology Laboratory of the
Detroit Medical Center (Detroit, MI, USA) from 1994 to 2002.
The original cultures, isolated from sputum, bronchial
wash and lungs of immunocompromised patients, were
subcultured on Sabouraud dextrose agar to check for purity
and viability. Working cultures were maintained on Sabou-
raud dextrose agar slants at 4C. For long-term preservation
of the cultures, conidial suspensions were prepared in
glycerol 25% v ⁄v and stored at ) 80C.
MIC determination
Conidial suspensions from 6-day-old A. fumigatus cultures
were prepared, standardised by haemocytometry, and used as
inocula for susceptibility testing. MICs of various antifungal
agents for A. fumigatus isolates were determined in RPMI-1640
by the M38-A broth microdilution technique recommended by
the National Committee for Clinical Laboratory Standards [15],
except that the MIC was defined as the concentration of drug
that produced no visible growth (MIC-0). Drug concentrations
ranging from either 0.015 to 16 mg ⁄L (triazoles, amphotericin
B, amphotericin B lipid complex and liposomal amphotericin
B) or 0.062 to 64 mg ⁄L (nikkomycin Z and caspofungin) or 0.25
to 256 mg ⁄L (micafungin) were used for MIC determinations.
Where applicable, comparable concentrations of dime-
thylsulphoxide were used as controls. Each MIC determination
was repeated at least once, with results that were either the
same or ± 1 two-fold dilution.
MEC determination
The MECs (minimum effective concentrations) of caspofungin
and micafungin for A. fumigatus isolates were determined in
RPMI-1640 with the M38-A broth microdilution technique [15].
The MEC was defined as the lowest concentration of the drug
that produced a marked morphological change in the hyphae,
from profuse mycelial growth producing straight, sparsely
branching hyphal filaments to hyper-branching, crooked
hyphae showing stunted growth, resulting in the production
of microcolonies. The echinocandin-induced transition from
the normal profuse hyphal growth to microcolonies was easily
recognised with the aid of an MIC plate-viewing mirror. The
concentrations of caspofungin and micafungin used for MEC
determination ranged from 0.0019 to 2 mg ⁄L. The MEC
determination was repeated once, with results that were
almost identical.
Fractional inhibitory concentration index determination
The in-vitro susceptibility of A. fumigatus to two-drug
combinations of nikkomycin Z with various polyenes, triaz-
oles or echinocandins was evaluated with the fractional
inhibitory concentration index (FICI) method. The FICI was
determined with a two-dimensional chequerboard in a
microtitre plate with the M38-A broth microdilution tech-
nique [15]. Pairwise combinations of the required concentra-
tions of antifungal drug A and antifungal drug B were
prepared in two-fold increments in 0.1-mL aliquots of RPMI-
1640 containing 0.165 M MOPS buffer (pH 7.0). Appropriate
drug-free growth controls were included. To each well,
0.1 mL of fresh conidial suspension (2 · 104 conidia ⁄mL) was
added. The contents of each well were mixed by repeated
pipetting back and forth with a multichannel pipette. The
microtitre plate was incubated at 35C for 48 h, after which
fungal growth was assessed by reduction of the tetrazolium
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compound 3-(4,5-dimethyl-2-thiazolyl)-2,5-diphenyl-2H-tetra-
zolium bromide (MTT assay). Briefly, after 48 h of growth,
medium was removed from each well with a multichannel
pipette, and 0.1 mL of fresh RPMI-1640 was added, followed
by 0.025 mL of MTT solution (1 g ⁄L) containing 0.2 mM
(final concentration) menadione. Following incubation for 3 h
at 35C, fungal cells were stained blue following accumula-
tion of the MTT–formazan insoluble salts in the mycelia. A
well representing the lowest concentration(s) of the drug(s)
with no visible colour was taken as the endpoint. The MIC
was defined as the lowest concentration of the drug that
showed no visible growth (MIC-0). The FICI was calculated
with the formula:
FICI ¼ ðAc=AaÞ þ ðBc=BaÞ
where Ac and Bc are the MICs of drugs A and B in
combination, and Aa and Ba are the MICs of drugs A and B.
The drug interactions were classified as synergic
(FICI £ 0.5), no interaction (FICI > 0.5, but £ 4) or antagonistic
(FICI > 4). In addition, the FICI was determined for caspofun-
gin and micafungin in two-drug combinations with nikkomy-
cin Z, using the MEC endpoints as described above.
Kill-curve study
The fungicidal activity of nikkomycin Z alone and in combi-
nation with caspofungin or voriconazole against A. fumigatus
strains W73355 and H50246 was determined in kill-curve
experiments. Aliquots (5 mL) of germinated (6 h at 35C)
conidia prepared in RPMI-1640 (1 · 106 conidia ⁄mL) were
incubated at 35C in the presence of nikkomycin Z, caspofun-
gin, or nikkomycin Z plus caspofungin, at concentrations
ranging from 0.25 mg ⁄L to 32 mg ⁄L (0.004 ·MIC-0 to
0.5 · MIC-0). Similarly, to study the fungicidal activity of
nikkomycin Z in combination with a triazole, conidia were
incubated with either nikkomycin Z (1 mg ⁄L and 16 mg ⁄L;
0.0156 · MIC-0 and 0.25 · MIC-0, respectively), voriconazole
(0.25 mg ⁄L and 0.5 mg ⁄L; 0.5 · MIC-0 and 1 · MIC-0, respect-
ively), or nikkomycin Z plus voriconazole combinations, at the
same concentrations. At 0, 3, 6, 9, 12 and 24 h, 0.1-mL aliquots
of the conidial suspension were removed and diluted to obtain
10–104-fold dilutions, and 0.1-mL aliquots were spread in
duplicate on Sabouraud dextrose agar plates. The plates were
incubated at 35C for 48 h, and the number of CFU ⁄mL was
determined. Kill-curves were constructed by plotting mean
log10 CFU ⁄mL against the time of exposure of conidia to
antifungal drugs.
Fungal cell viability test
A. fumigatus conidia (1 · 106 ⁄mL) were germinated in RPMI-
1640 for 6 h at 35C in the wells of 96-well microtitre plates. At
the end of the germination period, nikkomycin Z or caspo-
fungin, or a combination of these drugs, was added to replicate
wells to final concentrations ranging from 0.25 mg ⁄L
(0.004 · MIC-0) to 16 mg ⁄L (0.25 · MIC-0). The germinated
conidia were incubated with the drug(s) at 35C for 24 h, the
medium was removed, and the viability of the drug-treated
germinated conidia was examined with the MTT assay as
described above. The development of blue colour following
the accumulation of formazan salt in the mycelia as a result of
MTT reduction suggests the presence of viable cells.
RESULTS AND DISCUSSIONS
In-vitro susceptibility
The in-vitro susceptibilities of 20 clinical isolates
of A. fumigatus to ten antifungal drugs belonging
to four classes are shown in Table 1. All of the
isolates were highly susceptible to triazoles, with
a narrow range (0.062–0.5 mg ⁄L) of MIC-0 values.
The conventional and lipid formulations of amph-
otericin B were less active (MIC-0 0.5–4 mg ⁄L)
against A. fumigatus than were the triazoles.
Amphotericin B and amphotericin B lipid com-
plex had similar MIC-0 values, whereas that of
liposomal amphotericin B was 2–4-fold higher.
The MIC-0 values of nikkomycin Z (16–64 mg ⁄L)
and the echinocandins (32 to > 256 mg ⁄L) for
A. fumigatus were high compared to those of
polyenes and triazoles. Since the MIC-0 values of
echinocandins are many-fold above the levels of
the drug achievable in blood and tissues, previous
investigators have used an alternative clinically
relevant endpoint to evaluate their effectiveness.
However, in the present study, the MECs of
caspofungin and micafungin were at least 250-
fold (caspofungin) to 16 500-fold (micafungin)
lower than the MIC-0 values.
Effect of two-drug combinations
Table 2 shows that two-drug combinations of
nikkomycin Z with either conventional or lipid
formulations of amphotericin B or triazoles had
no specific synergic effects on A. fumigatus.
However, the FICIs obtained for nikkomycin Z
in combination with the polyenes (3.59 ± 0.57 and
3.95 ± 0.74) were c. two-fold higher than those
obtained for nikkomycin Z in combination with
Table 1. In-vitro susceptibility of clinical isolates of
Aspergillus fumigatus (n = 20) to antifungal drugs
Antifungal
drug
MIC (mg ⁄L)
range MIC50 (mg ⁄L) MIC90 (mg ⁄L)
Nikkomycin 16–64 64 64
Amphotericin B 0.5–2 1 2
Amphotericin B
lipid complex
0.5–2 1 2
Liposomal
amphotericin B
2–4 2 4
Itraconazole 0.25–0.5 0.25 0.5
Voriconazole 0.25–0.5 0.25 0.25
Posaconazole 0.062–0.25 0.125 0.125
Ravuconazole 0.25–0.5 0.25 0.5
Caspofungina 32–64 (0.125–0.25) 64 (0.25) 64 (0.25)
Micafungina 64 to > 256 (0.0019–0.0156) > 256 (0.0019) > 256 (0.0156)
aValues shown in parentheses for caspofungin and micafungin represent MECs.
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triazoles (1.07 ± 0.37 and 2.20 ± 0.44). In contrast,
the FICIs obtained for two-drug combinations of
nikkomycin Z with caspofungin (0.22 ± 0.19) or
micafungin (0.35 ± 0.27) were substantially lower
than 0.5, indicating synergic action against
A. fumigatus. Moreover, the FICIs obtained for
nikkomycin Z in combination with either caspo-
fungin or micafungin by the MEC-endpoint
method were similar to those obtained when
MIC-0 was used as an endpoint, suggesting that
both MEC and MIC-0 endpoints could be used to
study the interaction of two-drug combinations of
nikkomycin Z with echinocandin compounds.
Fungicidal activity
Since the echinocandins in two-drug combina-
tions with nikkomycin Z produced a synergic
action against A. fumigatus, the fungicidal activity
of pairwise combinations of nikkomycin Z and
caspofungin were examined at concentrations
ranging from 0.25 to 32 mg ⁄L (0.004 · MIC-0 to
0.5 · MIC-0) against A. fumigatus. Neither nikko-
mycin Z nor caspofungin alone showed fungici-
dal activity against A. fumigatus at concentrations
as high as 64 mg ⁄L (1 · MIC-0) compared to the
drug-free control. However, a combination of the
two drugs at ‡ 2 mg ⁄L (0.031 · MIC-0) killed
A. fumigatus conidia in a concentration-dependent
manner within 24 h, whereas no substantial kill-
ing of conidia was obtained with combinations of
these drugs below 2 mg ⁄L. For example, nikko-
mycin Z and caspofungin at 32 mg ⁄L each
(0.5 · MIC-0) killed > 99% of conidia within
24 h of exposure to the drugs (Fig. 1A), whereas
a combination of caspofungin at 0.25 mg ⁄L and
nikkomycin Z at 1 mg ⁄L showed no fungicidal
activity (Fig. 1B).
In addition to the time-kill experiments, the
fungicidal activities of nikkomycin Z and caspo-
fungin were investigated, both alone and in
combinations, on germinated conidia of A. fumig-
atus with the fungal cell viability test. Neither
nikkomycin Z nor caspofungin, alone or in two-
drug combinations at concentrations £ 2 mg ⁄L
(0.031 · MIC-0), showed fungicidal activity
against A. fumigatus conidia germinated for 6 h.
Combinations of drugs, but not individual drugs,
at concentrations ‡ 8 mg ⁄L (0.125 · MIC-0) killed
germinated conidia completely, as these cells were
unable to reduce MTT. The number of CFUs
obtained from each well was found to correlate
with the presence of blue colour.
Table 2. Interaction of nikkomycin Z in two-drug combi-
nations with polyenes, triazoles and echinocandins against
Aspergillus fumigatus
Drug combination FICI ± SD Drug interaction
NKZ + AMB 3.59 ± 0.57 No interaction
NKZ + ABLC 3.95 ± 0.74 No interaction
NKZ + L-AMB 3.62 ± 0.98 No interaction
NKZ + ITZ 2.00 ± 0.0 No interaction
NKZ + VCZ 1.07 ± 0.37 No interaction
NKZ + PCZ 2.20 ± 0.44 No interaction
NKZ + RCZ 1.76 ± 0.44 No interaction
NKZ + CFG 0.22 ± 0.19 Synergy
NKZ + MFG 0.35 ± 0.27 Synergy
NKZ, nikkomycin Z; AMB, amphotericin B; ABLC, amphotericin B lipid complex;
L- AMB, liposomal amphotericin B; ITZ, itraconazole; VCZ, voriconazole; PCZ,
posaconazole; RCZ, ravuconazole; CFG, caspofungin; MFG, micafungin.
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Fig. 1. In-vitro fungicidal activities of (A) high and (B) low
concentrations of nikkomycin Z in combination with high
and low concentrations of caspofungin against Aspergillus
fumigatus. Each point represents the mean of two inde-
pendent experiments in which A. fumigatus strains W73355
and H50246 were used. The vertical bars denote twice the
standard deviation. CFG 0.25, caspofungin 0.25 mg ⁄L;
CFG 32, caspofungin 32 mg ⁄L; NKZ 1, nikkomycin Z
1 mg ⁄L; NKZ 32, nikkomycin Z 32 mg ⁄L.
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The fungicidal activity of nikkomycin Z was
also investigated in combination with voriconaz-
ole, a representative of the triazoles. Conidia
exposed to nikkomycin Z at 1 mg ⁄L and 16 mg ⁄L
for 24 h at 35C showed no reduction in CFU ⁄mL
compared to the drug-free control. Voriconazole
at 0.25 mg ⁄L and 0.5 mg ⁄L (0.5 · MIC-0 and
1 · MIC-0) reduced the viable count by > 95%
within 24 h. No enhanced killing was obtained
when nikkomycin Z at 1 mg ⁄L and 16 mg ⁄L was
added to voriconazole at 0.25 mg ⁄L and
0.5 mg ⁄L, respectively (Fig. 2).
Combinations of antifungal drugs belonging to
different classes with distinct modes of action
have the highest potential for synergic interaction.
The in-vitro synergic action of nikkomycin Z in
two-drug combinations with itraconazole [16],
micafungin [17] and the echinocandin anidula-
fungin (formerly known as LY303366) [14,18]
against A. fumigatus has been studied previously
with the FICI method. With the use of a nikko-
mycin Z MIC endpoint defined on the basis of
partial growth inhibition, it was shown in these
studies that anidulafungin plus nikkomycin Z, or
micafungin plus nikkomycin Z, showed synergic
action against A. fumigatus; these results are in
agreement with the present data obtained for two-
drug combinations of nikkomycin Z with caspo-
fungin or micafungin. On the other hand, Li and
Rinaldi [16] reported that a combination of itrac-
onazole and nikkomycin Z showed synergic
action against A. fumigatus. In the present study,
the FICI value (2.00 ± 0.0) obtained for the nik-
komycin Z plus itraconazole combination indica-
ted no drug interaction.
The fungicidal activity of nikkomycin Z plus
caspofungin against A. fumigatus is intriguing,
since neither nikkomycin Z nor caspofungin
alone show fungicidal activity against this fila-
mentous fungus. Inhibition of glucan or chitin
synthesis in itself, by caspofungin or nikkomycin
Z, appears to be inadequate to inhibit the forma-
tion of cell walls completely in A. fumigatus, and
the resulting microcolonies are metabolically
functional, although colonies grown in the pres-
ence of caspofungin have profoundly altered
hyphal morphology [19]. However, a combina-
tion of nikkomycin Z and caspofungin will inhibit
the synthesis of glucan and chitin simultaneously,
resulting in complete inhibition of cell wall
synthesis. In the absence of an intact functional
cell wall, the fungal cell is highly susceptible to
osmotic pressure and lysis, resulting in death.
Overall, the present results show that two cell
wall-specific fungistatic drugs with weak activity
against A. fumigatus exert potent fungicidal activ-
ity when combined.
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